← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › VACCINES › BACTERIAL AND VIRAL VACCINES, COMBINED › Bacterial and viral vaccines, combined
diphtheria-haemophilus influenzae B-pertussis-tetanus-hepatitis B-meningococcus A + C
J07CA13
Forms & Strengths
- Suspension for injection: diphtheria toxoid 30 IU, haemophilus influenzae type B 10 mcg, pertussis toxoid 40 IU, tetanus toxoid 40 IU, hepatitis B surface antigen 10 mcg, meningococcus A 5 mcg, meningococcus C 5 mcg
- Single dose vials or prefilled syringes
Adult Dosing
- Not recommended for use in adults, only for pediatric use
- Catch-up vaccination may be recommended for certain adults with high risk of exposure or disease
Pediatric Dosing
- Primary series: 3 doses (at 2, 4, and 6 months of age) of 0.5 mL each
- Booster dose: 1 dose (at 12-18 months of age) of 0.5 mL
Indications
- Active immunization against diphtheria, haemophilus influenzae type b, pertussis, tetanus, hepatitis B, and meningococcal A and C disease
- Prevention of invasive meningococcal disease caused by serogroups A and C
Mechanism of Action
- Induces immunity by stimulating the body to produce antibodies against diphtheria toxoid, haemophilus influenzae type B, pertussis toxoid, tetanus toxoid, hepatitis B surface antigen, and meningococcal A and C polysaccharides
- Enhances immune response through conjugation of meningococcal polysaccharides to carrier proteins
Contraindications
- Severe allergic reaction to any component of the vaccine or after a previous dose
- Encephalopathy within 7 days of a previous pertussis-containing vaccine
Adverse Reactions
- Pain, redness, and swelling at the injection site
- Fever, irritability, and loss of appetite
- Allergic reactions, such as hives, itching, and difficulty breathing
Drug Interactions
- Administer with caution in patients receiving immunosuppressive therapy
- May interfere with tuberculin skin test results for up to 6 weeks after vaccination
Curated Content: Needs Vetting Before Put to Clinical Use